Skip to main content
SpringerLink
Log in

Place of Parenteral Cephalosporins in the Ambulatory Setting

Clinical Evidence

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

During the last decade, 6 parenteral third generation cephalosporins have been introduced into clinical practice. The three most frequently used agents are cefotaxime, ceftazidime and ceftriaxone. Although primarily used in hospitals, these agents are increasingly employed in the ambulatory setting. In particular, ceftriaxone, because of its favourable pharmacokinetic profile allowing once-daily administration by a bolus injection, has demonstrated both tolerability and efficacy in the ambulatory setting during extensive worldwide use. Sophisticated parenteral infusion systems enable cephalosporins that require more frequent administration to be delivered in this setting.

In noncomparative studies involving a range of patient populations and serious infections (mostly bone, joint and soft tissue, and pneumonia and febrile episodes in neutropenia), these cephalosporins achieved equivalent efficacy and tolerability, and considerable cost savings, since patients were able to receive all or part of their treatment in the home or outpatient setting. However, more comparative studies of ambulatory parenteral therapy in the inpatient setting or ambulatory oral therapy are necessary to further clarify the true cost effectiveness of this type of healthcare delivery. This is increasingly relevant in countries where parenteral antimicrobials are not the ‘standard of care’ in managing many serious infections.

Published experience to date confirms that third generation cephalosporins, particularly ceftriaxone, should have an essential place in the therapeutic formulary of any ambulatory parenteral antibiotic programme.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Bamberger DM, Dahl SL. Impact of voluntary vs enforced compliance of third-generation use in a teaching hospital. Ann Intern Med 1992; 152: 554–7

    Article  CAS  Google Scholar 

  2. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Med J Aust 1990; 153: 516–8

    PubMed  CAS  Google Scholar 

  3. MacGregor RR, Graziani A. Oral administration of antibiotics: a rational alternative to parenteral route. Clin Infect Dis 1997; 24: 457–67

    Article  PubMed  CAS  Google Scholar 

  4. Bartlett JG. Impact of new oral antibiotics on the treatment of infectious diseases. Infect Dis Clin Pract 1993; 2: 405–13

    Article  Google Scholar 

  5. Halls GA. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother 1993; 31: 985–1000

    Article  PubMed  CAS  Google Scholar 

  6. Tice AD. Outpatient parenteral antibiotic therapy in different countries. Int J Infect Dis 1996; 1: 102–6

    Article  Google Scholar 

  7. Tice AD. Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 655–61

    Article  PubMed  CAS  Google Scholar 

  8. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient antibiotics: a review of the literature. Am J Med 1989; 87: 301–5

    Article  PubMed  CAS  Google Scholar 

  9. Poretz DM, Wollard D, Eron LJ, et al. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77 Suppl. 4C: 77–83

    PubMed  CAS  Google Scholar 

  10. Daly PB, Evans JH, Kobayashi RH, et al. Home based immunoglobulin infusion therapy: quality of life and patient health perceptions. Ann Allergy 1991; 67: 504–10

    PubMed  CAS  Google Scholar 

  11. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients, and antimicrobial agents. Int J Antimicrob Agents 1995; 5: 3–8

    Article  PubMed  CAS  Google Scholar 

  12. Kunkel MJ. Quality assurance. Hosp Pract 1993; 28 Suppl. 1: 33–8

    Google Scholar 

  13. Conlon CP Outpatient intravenous antibiotic therapy. J Antimicrob Chemother 1996; 38: 557–9

    Article  PubMed  CAS  Google Scholar 

  14. Nathwani D, Seaton A, Davey P. Key issues in the development of a non-inpatient intravenous (NIPIV) antibiotic therapy programme —a European perspective. Rev Med Microbiol 1997; 8(3): 137–48

    Article  Google Scholar 

  15. Vinks AATMM, Touw DJ, Heijerman HGM, et al. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994; 16(4): 341–8

    Article  PubMed  CAS  Google Scholar 

  16. Tice AD, Slama TG, Berman S, et al. Managed care and the infectious diseases specialist. Clin Infect Dis 1996; 23: 341–68

    Article  PubMed  CAS  Google Scholar 

  17. Anonymous. Canadian Home IV Guidelines. Canadian Advisory Committee on Home IV Antibiotic Therapy. Toronto, Canada: Canadian Advisory Committee, 1994: 1–8

  18. Nathwani D, Tillotson G, Davey P. Sequential antibiotic therapy —the role of quinolones. J Antimicrob Chemother 1997; 39(4): 441–6

    Article  PubMed  CAS  Google Scholar 

  19. Huchon GJ, Gialdroni-Grassi G, Leophonte P, et al. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Resp J 1996; 9: 1590–5

    Article  CAS  Google Scholar 

  20. Misan GMH, Dollman C, Shaw D, et al. Cephalosporin utilisation review and utilisation. Pharmacoeconomics 1995; 8(2): 100–22

    Article  PubMed  CAS  Google Scholar 

  21. Adu AA, Armour CL. Drug Utilisation Review (DUR) of the third generation cephalosporins. Drugs 1995; 50(3): 423–39

    Article  PubMed  CAS  Google Scholar 

  22. Mandell LA, Bergeron MG, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Can J Infect Dis 1995; 6(6): 306–15

    PubMed  CAS  Google Scholar 

  23. Hamilton-Miller JMT. Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infect Dis 1996; 2: 12–20

    Article  Google Scholar 

  24. Nathwani D. Outpatient treatment with teicoplanin. Chemotherapie J 1996; 5 Suppl. 11: 35–8

    Google Scholar 

  25. Wilson APR, Gruneberg RN. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis 1994; 13: 701–10

    Article  PubMed  CAS  Google Scholar 

  26. Davis R, Bryson HM. Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics 1994; 6(3): 249–69

    CAS  Google Scholar 

  27. Talan DA. Infectious disease issues in the emergency department. Clin Infect Dis 1996; 23: 1–14

    Article  PubMed  CAS  Google Scholar 

  28. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis 1995; 14: 636–42

    Article  PubMed  CAS  Google Scholar 

  29. Jauregui LE, Martin M, Hageage G. Clinical evaluation of ceftriaxone therapy in the out-patient setting. Insights into the Treatment of Serious Infections 1988; 2: 186–94

    Google Scholar 

  30. Eron LJ, Park CH, Hixon DH, et al. Ceftriaxone therapy of bone and soft tissue infections in the outpatient and hospital settings. Antimicrob Agents Chemother 1983; 23: 731–7

    Article  PubMed  CAS  Google Scholar 

  31. Stamboulian D, Bonvehi P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991; 13 Suppl. 2: S160–3

    Article  PubMed  Google Scholar 

  32. Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with a single dose of ceftriaxone sodium for 4 weeks. JAMA 1992; 267: 264–7

    Article  PubMed  CAS  Google Scholar 

  33. Francioli P, Ruch W, Stamboulian D and the International Infective Endocarditis Study Group. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicentre study. Clin Infect Dis 1995; 21: 1406–10

    Article  PubMed  CAS  Google Scholar 

  34. Karachalios GN, Georgiopoulos AN, Kanatakis S. Treatment of various infections in an outpatient practice by intramuscular ceftriaxone: home parenteral therapy. Chemotherapy 1989; 35: 389–92

    Article  PubMed  CAS  Google Scholar 

  35. Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother 1988; 32: 1439–40

    Article  PubMed  CAS  Google Scholar 

  36. Bass JW, Steele RW, Wittler RR, et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J 1993; 12: 466–73

    Article  PubMed  CAS  Google Scholar 

  37. Preis S, Jugens H, Friedland C, et al. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient basis. Klin Padiatr 1993; 205: 295–9

    Article  PubMed  CAS  Google Scholar 

  38. Martino P, Girmenia C, Raccah R, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992; 49: 49–52

    Article  PubMed  CAS  Google Scholar 

  39. Kaplinsky C, Drucker M, Goshen J, et al. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994; 30: 649–51

    PubMed  CAS  Google Scholar 

  40. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847–9

    Article  PubMed  CAS  Google Scholar 

  41. Leibovitz E, Tabachnik E, Fliedel O, et al. Once-daily intramuscular ceftriaxone in the outpatient treatment of severe community acquired pneumonia in children. Clin Pediatr 1991; 29: 634–9

    Article  Google Scholar 

  42. Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J 1988; 7: 160–4

    Article  PubMed  CAS  Google Scholar 

  43. Dagan R, Einhorn M. A program of outpatient parenteral antibiotic therapy for serious pediatric bacterial infections. Rev Infect Dis 1991; 13 Suppl. 2: S152–5

    Article  PubMed  Google Scholar 

  44. McCarthy CA, Powell KR, Jaskiewicz JA, et al. Outpatient management of selected infants younger than two months of age evaluated for possible sepsis. Pediatr Infect Dis J 1990; 9: 385–9

    Article  PubMed  CAS  Google Scholar 

  45. Baskin MC, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120: 22–7

    Article  PubMed  CAS  Google Scholar 

  46. Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97 Suppl. 2A: 28–33

    Article  PubMed  CAS  Google Scholar 

  47. Williams DN, Bosch D, Boots J, et al. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. Clin Ther 1993; 15(1): 169–79

    PubMed  CAS  Google Scholar 

  48. Mauceri AA and the HIAT Group. Treatment of bone and joint infections utilising a third generation cephalosporin with an outpatient drug delivery device. Am J Med 1994; 97 Suppl. 2A: 14–22

    Google Scholar 

  49. Poretz DM and the HIAT Group. Treatment of skin and soft tissue infections utilising an outpatient parenteral drug delivery device: a multicenter trial. Am J Med 1994; 97 Suppl. 2A: 23–7

    Google Scholar 

  50. Williams DN. Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: results with a computerised ambulatory drug delivery system. Am J Med 1994; 97 Suppl. 2A: 50–5

    Article  PubMed  CAS  Google Scholar 

  51. Poretz DM and the HIAT Group. Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery device: global analysis of a large-scale, multicenter trial. Am J Med 1994; 97 Suppl. 2A: 34–42

    Google Scholar 

  52. Angel JVG and the HIAT Group. Outpatient antibiotic therapy for elderly patients. Am J Med 1994; 97 Suppl. 2A: 43–9

    Google Scholar 

  53. Morales JO, Behren LV. Secondary bacterial infections in the HIV-infected patients: an alternative ambulatory outpatient treatment utilising intravenous cefotaxime. Am J Med 1994; 97 Suppl. 2A: 9–13

    Article  PubMed  CAS  Google Scholar 

  54. Tice A. Once-daily ceftriaxone outpatient therapy in adults with infections. Chemotherapy 1991; 37 Suppl. 3: 7–10

    Article  PubMed  Google Scholar 

  55. Parker S, Nathwani D, O'Reilly D, et al. Evaluation of the impact of non-inpatient iv antibiotic treatment for acute infections on the hospital, primary care services and the patient. J Antimicrob Chemother 1998; 42: 373–80

    Article  PubMed  CAS  Google Scholar 

  56. Lieu TA, Baskin MN, Schwartz S, et al. Clinical and cost-effectiveness of outpatient strategies for the management of febrile infants. Pediatrics 1992; 89: 1135–44

    PubMed  CAS  Google Scholar 

  57. van der Laag J, van de Weg L. Cystic fibrosis and outpatient treatment with parenteral antibiotics in children. Int J Antimicrob Agents 1995; 5: 63–6

    Article  PubMed  Google Scholar 

  58. Millar LK, Wing D, Paul RH, et al. Outpatient treatment of pyelonephritis in pregnancy: a randomized controlled trial. Obstet Gynecol 1995; 86(4): 560–4

    PubMed  CAS  Google Scholar 

  59. Koeesim M, Ronald A, Plummer FA, et al. Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycyline versus ampicillin-sulbactam. Antimicrob Agents Chemother 1991; 35(8): 1651–6

    Article  Google Scholar 

  60. Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24: 170–8

    Article  PubMed  CAS  Google Scholar 

  61. New PB, Swanson GF, Bulich RG, et al. Ambulatory antibiotic infusion devices: extending the spectrum of outpatient therapies. Am J Med 1991; 91: 455–61

    Article  PubMed  CAS  Google Scholar 

  62. Nathwani D, Conlon C. Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a Working Party. Clin Microbiol Infect Dis 1998; 4: 537–51

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infection & Immunodeficiency Unit, Kings Cross Hospital, Tayside University NHS Trust, Dundee, DD3 8EA, Scotland

    Dilip Nathwani

Authors
  1. Dilip Nathwani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nathwani, D. Place of Parenteral Cephalosporins in the Ambulatory Setting. Drugs 59 (Suppl 3), 37–46 (2000). https://doi.org/10.2165/00003495-200059003-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059003-00005

Keywords

Search

Navigation